Boosting leukemia-specific T cell responses in patients following stem cell transplantation

Abstract

Whole tumor cell-based vaccines administered within the first 2 to 3 months after allogeneic stem cell transplantation stand out as a promising approach to enhance graft-vs.-leukemia responses. Herein, the implications of this finding for the development of strategies to improve the outcome of patients subjected to allogeneic stem cell transplantation are discussed.

Keywords: :

• cancer vaccines
• CLL
• immune reconstitution
• multiepitope vaccines
• neoantigens
• stem cell transplantation
• whole tumor-cell vaccination

Citation: Burkhardt UE, Wu CJ. Boosting leukemia-specific T cell responses in patients following stem cell transplantation. OncoImmunology 2013; 2:e26587; 10.4161/onci.26587

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

U.E.B. acknowledges support from the German Research Foundation (BU 3028/1–1).